Pharmaxis partners cystic fibrosis drug Bronchitol with Chiesi in the US
Executive Summary
After struggling to bring the product to market on its own, Pharmaxis Ltd. secured Chiesi Farmaceutici SPA as its exclusive US partner for the cystic fibrosis candidate Bronchitol (mannitol), which is administered via a dry-powder inhaler. (Bronchitol is already sold in the EU.)
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice